GV participated in a series C round that lifted the coronavirus treatment and preventative agent developer's overall funding to $466m.

Adagio Therapeutics, a US-headquartered developer of antibody-based coronavirus treatments, closed a $336m series C round today featuring biotech company Adimab and GV, a subsidiary of internet and technology group Alphabet.

RA Capital Management led the round, which included investment and financial services group Fidelity, Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, OrbiMed, Polaris Partners, Mithril, Population Health Partners and Omega Funds.

Founded in 2020, Adagio is developing treatments for coronaviruses, and its lead product candidate, ADG20, is a…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn